COMMUNIQUÉS West-GlobeNewswire

Elutia to Participate in Upcoming Investor Conferences
27/08/2025
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, [...]
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
27/08/2025
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported [...]
Septerna to Participate in Upcoming Investor Conferences
27/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today [...]
Protara Therapeutics to Participate in Upcoming Investor Conferences
27/08/2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
27/08/2025
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating [...]
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
27/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
27/08/2025
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that [...]
Soleno Therapeutics to Participate in Upcoming September Conferences
27/08/2025
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
MIMEDX to Participate in Upcoming Investor Conferences
27/08/2025
MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
27/08/2025
Cambridge, UK, 27 August 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
27/08/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 27 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
27/08/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE [...]
Idorsia successfully completes convertible bonds restructuring
27/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025 Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 ( CB 2025 [...]
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
27/08/2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Halle (Saale) / Munich, Germany, August 27 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
27/08/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases [...]
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
27/08/2025
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Immuron partners with InvestorHub
27/08/2025
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides [...]
SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
26/08/2025
SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the [...]
NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share
26/08/2025
EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board [...]

Pages